Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 14/20 | 0.72 |
| ▸ | KCNQ2 | O43526 | 14/20 | 0.72 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706798 | 1.00 | KCNQ3 (0.72) | KCNQ3KCNQ2TGFBR1KCNQ4KCNQ5 | |
| SCHEMBL3702403 | 0.88 | KCNQ3 (0.57) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3702402 | 0.88 | KCNQ3 (0.57) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3693043 | 0.86 | KCNQ2 (0.55) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3693048 | 0.86 | KCNQ2 (0.55) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3704479 | 0.83 | KCNQ3 (0.73) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3704476 | 0.83 | KCNQ3 (0.73) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3705797 | 0.83 | KCNQ3 (0.60) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3705793 | 0.83 | KCNQ3 (0.60) | KCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL3704943 | 0.82 | KCNQ3 (0.59) | KCNQ3KCNQ2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | claimed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | claimed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| US-8609669-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| WO-2012067822-A1 | PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122888-A1 | Potassium Channel Modulators | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122888-A1 | Potassium Channel Modulators | KCNQ1, KCNQ2, KCNJ2 | KCNQ3 4/4885KCNQ2 2/4885TGFBR1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.